KZR · Kezar Life Sciences
Acquired Company
Aurinia Pharmaceuticals (Aurinia Pharma U.S., Inc.) completed its acquisition of Kezar Life Sciences on May 11, 2026, pursuant to a tender offer and merger for $6.955 per share in cash plus one contingent value right (CVR).
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Market Cap
53.86M
52 Wk Range
$3.53 - $7.55
Previous Close
$7.29
Open
$7.29
Volume
N/A
Day Range
$7.29 - $7.29
Enterprise Value
-15.81M
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
15.78%
Institutional Own.
61.26%
Qtr Updated
N/A